United States of America
Dr. Jamie Topper is a Managing General Partner of Frazier Healthcare Partners’ Life Sciences team. Throughout his 11 years as a General Partner, Jamie has invested across over 20 companies encompassing a broad spectrum of Life Science and Biopharmaceutical companies. Dr. Topper has led and served as a board member for many of Frazier’s successful life sciences investments, including Calistoga Pharmaceuticals (co-founder, sold to Gilead), Rempex (sold to The Medicines Company), Incline (co-founder, sold to The Medicines Company), Alnara (sold to Lilly), Portola (co-founder, NASDAQ: PTLA), Cotherix (sold to Actelion), and Threshold (NASDAQ: THLD). In addition to Millendo, he currently represents Frazier on the boards of Alcresta, Allena Pharmaceuticals, Anaptys Biotech, Aptinyx, Entasis Therapeutics, Merganser Biotech, and ProNai Therapeutics (NASDAQ: DNAI). Prior to joining Frazier, Dr. Topper served as head of the cardiovascular research and development franchise at Millennium Pharmaceuticals and ran Millennium San Francisco (formerly COR Therapeutics). Before the merger of COR and Millennium, he served as the Vice President of Biology at COR and was responsible for all research activities. He served on the faculties of Stanford Medical School and Harvard Medical School prior to joining COR. Dr. Topper received his M.D. and Ph.D. in biophysics from Stanford University School of Medicine and holds a B.S. from the University of Michigan. He completed his postgraduate training in Internal Medicine and Cardiovascular Disease at the Brigham and Women's Hospital in Boston and is board certified in both disciplines. He has authored over 50 publications and was the recipient of a Howard Hughes Scholars Award while on the faculty at Stanford University. In 2011 and 2016, Dr. Topper was named to the Midas List of leading venture capitalists, and in 2013 was recognized by Forbes as one of the top 10 healthcare investors.